

TELEPHONE 512/474-5201
FACSIMILE 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

TECH CENTER 1600/2900

APR 23 2002

RECEIVED

April 15, 2002

FILE: ARCD:351US

RECEIVED
APR 23 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 15, 2002

Date

Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

RE: SN 09/930,559 "COMPOUNDS THAT ENHANCE TUMOR DEATH" – Glyn Dawson
and Seongeun Julia Cho (Client Reference: UCHI:812)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C38).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10107322/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

GNS/cmb
Encl: as noted



PATENT

TECH CENTER 1600/2900

APR 23 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Glyn Dawson
Seongeun Julia Cho

Serial No.: 09/930,559


Filed: August 15, 2001

For: COMPOUNDS THAT ENHANCE
TUMOR DEATH

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: ARCD:351US/GNS

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 15, 2002	
Date	Gina N. Shishima

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10107322/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 15, 2002

Form PTO-1449 (modified)

Atty. Docket No.
ARCD:351US/GNSSerial No.
09/930,559

List of Patents and Publications for Applicant's

Applicant
Glyn Dawson
Seongeun Julia ChoFiling Date:
August 15, 2001Group:
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



APR 23 2002

RECEIVED

TECH CENTER 1600 2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Camp and Hofmann, "Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-ras," <i>J. Biol. Chem.</i> 268:22566-22574, 1993.
	C2	Camp <i>et al.</i> , "Molecular cloning and expression of palmitoyl-protein thioesterase," <i>J. Biol. Chem.</i> 269:23212-23219, 1994.
	C3	Cho and Dawson, "Enzymatic and molecular biological analysis of palmitoyl protein thioesterase deficiency in infantile neuronal ceroid lipofuscinosis," <i>J. Neurochem.</i> 71:323-329, 1998.
	C4	Cho and Dawson, "Palmitoyl Protein Thioesterase 1 Protects Against Apoptosis Mediated by Ras-Akt-Caspase Pathway in Neuroblastoma Cells," <i>J. Neurochem.</i> , 74(4):1478-1488, 2000.
	C5	Cho <i>et al.</i> , "Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells," <i>J. Neurosci. Res.</i> , 62:234-240, 2000.
	C6	Cho <i>et al.</i> , "In Vitro Depalmitoylation of Neurospecific Peptides: Implication for Infantile Neuronal Ceroid Lipofuscinosis," <i>J. Neurosci. Res.</i> 59: 32-38, 2000.
	C7	Cho <i>et al.</i> , "Role of palmitoyl-protein thioesterase in cell death: implications for infantile neuronal ceroid lipofuscinosis," <i>European Journal of Paediatric Neurology</i> , 5(Suppl. A):53-55, 2001.
	C8	Crews <i>et al.</i> , "Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis," <i>Proc. Natl. Acad. Sci. USA</i> 93: 4316-4319, 1996.

25081275.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
ARCD:351US/GNSSerial No.
09/930,559

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Glyn Dawson
Seongeun Julia ChoFiling Date:
August 15, 2001Group:
1646

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

APR 23 2002

RECEIVED

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Crowder and Freeman, "Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons," <i>J. Neurosci.</i> , 18:2933-2943, 1998.
	C10	Dawson and Cho, "Batten's disease: clues to neuronal protein catabolism in lysosomes," <i>J. Neurosci. Res.</i> , 60:133-140, 2000.
	C11	Dawson <i>et al.</i> , "Chronic exposure to κ -opioids enhances the susceptibility of immortalized neurons (F-11 κ 7) to apoptosis-inducing drugs by a mechanism that may involve ceramide," <i>J. Neurochem.</i> , 68:2363-2370, 1997.
	C12	Duncan and Gilman, "A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein α subunits and p21 ^{RAS} ," <i>J. Biol. Chem.</i> , 273:15830-15837, 1998.
	C13	Edwards <i>et al.</i> , "Design, synthesis and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α -ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-Benzoxazole," <i>J. Am. Chem. Soc.</i> , 114:1854-1863, 1992.
	C14	Goswami and Dawson, "Does ceramide play a role in neural cell apoptosis?" <i>J. Neurosci. Res.</i> , 60:141-149, 2000.
	C15	Goswami <i>et al.</i> , "Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11 κ 7) neurons," <i>J. Neurochem.</i> , 70:1376-1382, 1998.
	C16	Goswami <i>et al.</i> , "Overexpression of Akt (Protein Kinase B) confers protection against apoptosis and prevents formation of ceramide in response to pro-apoptotic stimuli," <i>J. Neurosci. Res.</i> , 57:884-893, 1999.
	C17	Haimovitz-Friedman <i>et al.</i> , "Ceramide signaling in apoptosis," <i>Br. Med. Bull.</i> , 53:539-553, 1997.
	C18	Haklai <i>et al.</i> , "Dislodgment and accelerated degradation of Ras," <i>Biochemistry</i> , 37:1306-1314, 1998.
	C19	Hellsten <i>et al.</i> , "Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis," <i>EMBO J.</i> , 15:5240-5245, 1996.

25081275.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

APR 23 2002

TECH CENTER 160C

Form PTO-1449 (modified)

Atty. Docket No.
ARCD:351US/GNSSerial No.
09/930,559

List of Patents and Publications for Applicant's

Applicant
Glyn Dawson
Seongeun Julia Cho

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
August 15, 2001Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Huwiler <i>et al.</i> , "Physiology and pathophysiology of sphingolipid metabolism and signaling," <i>Biochimica Biophysica Acta.</i> , 1485:63-99, 2000.
	C21	Lawrence <i>et al.</i> , "Structure—activity studies of cerulenin analogues as protein palmitoylation inhibitors," <i>J. Med. Chem.</i> , 2: 4932-1941, 1999.
	C22	Meng <i>et al.</i> , "The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase," <i>Biochemistry</i> 37: 10488-10492, 1998.
	C23	Mizushima <i>et al.</i> , "Ceramide induces apoptosis via CPP32 activation," <i>FEBS Lett.</i> , 395:267-271, 1996.
	C24	Obeid <i>et al.</i> , "Programmed cell death induced by ceramide," <i>Science</i> , 259:1769-1771, 1993.
	C25	Sellers <i>et al.</i> , "Apoptosis and cancer drug targeting," <i>J. Clin. Invest.</i> , 104: 1655-1661, 1999.
	C26	Slee <i>et al.</i> , "Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrrolidine-containing α -Keto amide and hydroxyethylamine core structures," <i>J. Am. Chem. Soc.</i> , 117:11867-11878, 1995.
	C27	Soyombo and Hofmann, "Molecular cloning and expression of palmitoyl-protein thioesterase 2 (PPT2), a homolog of lysosomal palmitoyl-protein thioesterase with a distinct substrate specificity," <i>J. Biol. Chem.</i> , 272:27456-27463, 1997.
	C28	Steller, "Artificial death switches: induction of apoptosis by chemically induced caspase multimerization," <i>Proc. Natl. Acad. Sci. USA</i> , 95:5421-5422, 1998.
	C29	Sugimoto <i>et al.</i> , "Purification, cDNA cloning, and regulation of lysophospholipase from rat liver," <i>J. Biol. Chem.</i> , 271:7705-7711, 1996.
	C30	Suopanki <i>et al.</i> , "Palmitoyl-protein thioesterase, an enzyme implicated in neurodegeneration, is localized in neurons and is developmentally regulated in rat brain," <i>Neurosci Lett.</i> , 265:53-56, 1999.
	C31	Suopanki <i>et al.</i> , "The expression of palmitoyl-protein thioesterase is developmentally regulated in neural tissues but not in nonneural tissues," <i>Mol Genet Metab.</i> , 66:290-293, 1999.
	C32	Tergau <i>et al.</i> , "Inhibitors of ser/thr phosphatases 1 and 2A induced apoptosis in pituitary GH ₃ cells," <i>Naunyn-Schmiedeberg's Arch Pharmacol.</i> , 356:8-16, 1997.
	C33	Verheij <i>et al.</i> , "Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis," <i>Nature</i> , 380:75-79, 1996.

25081275.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
ARCD:351US/GNSSerial No.
09/930,559

List of Patents and Publications for Applicant's

Applicant
Glyn Dawson
Seongeun Julia ChoFiling Date:
August 15, 2001Group:
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

RECEIVED

APR 23 2002

TECH CENTER 1600 2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Verkruyse and Hofmann, "Lysosomal targeting of palmitoyl-protein thioesterase," <i>J. Biol. Chem.</i> , 271:15831-15836, 1996.
	C35	Vesa <i>et al.</i> , "Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis," <i>Nature</i> , 376:584-587, 1995.
	C36	Vojtek and Der, "Increasing complexity of the Ras signaling pathway," <i>J. Biol. Chem.</i> , 273:19925-19928, 1998.
	C37	Wiesner and Dawson, "Programmed cell death in neurotumour cells involves the generation of ceramide," <i>Glycoconjugate J.</i> , 13:327-333, 1996.
	C38	Wiesner and Dawson, "Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway," <i>J. Neurochem.</i> , 66:1418-1425, 1996.

25081275.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)